Research programme: cancer therapeutics - AbbVie / Philogen
Latest Information Update: 21 Jan 2016
At a glance
- Originator AbbVie; Philogen
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Inflammation
Most Recent Events
- 21 Jan 2016 Early research in Inflammation in USA and Italy (unspecified route) before January 2016 (Philogen Pipeline, January 2016)